Pleiotropic effects of ARB in metabolic syndrome

Current Vascular Pharmacology

Volumn 9, Issue 2, 2011, Pages 158-161

  Yamada, Satoru ^a  

^a KITASATO INSTITUTE HOSPITAL   (Japan)

Author keywords

Adiponectin; ARBs; NAFLD; PPAR gamma

Indexed keywords

ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; DELAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; LOSARTAN; OLMESARTAN; PERINDOPRIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; RAMIPRIL; TELMISARTAN; TRIACYLGLYCEROL;

ARTICLE; BLOOD PRESSURE; DIET THERAPY; DRUG MEGADOSE; EXERCISE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIVER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PLEIOTROPY; PREHYPERTENSION;

ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION; METABOLIC SYNDROME X; PPAR GAMMA; RENIN-ANGIOTENSIN SYSTEM;

EID: 79951701407     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016111794519318     Document Type: Article

References (56)

1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-53.
2. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999; 16: 442-3.
3. Einhorn D, Reaven GM, Cobin RH, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9(Suppl 2): 237-52.
4. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults: executive summary of the third report of the national cholesterol education program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
5. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA. Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute Scientific statement. Circulation 2005; 112: 2735-52.
6. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome: new world-wide definition from the International Diabetes Federation Consensus. Lancet 2005; 366: 1059-62.
7. Japanese Committee to Evaluate Diagnostic Standards for Metabolic Syndrome. Definition and the diagnostic standard for metabolic syndrome. Nippon Naika Gakkai Zasshi 2005; 94: 794-809 (in Japanese).
8. Itoh H. Metabolic Domino: new concept in lifestyle medicine. Drugs Today (Barc) 2006; 42 (suppl C): 9-16.
9. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/ angiotensin II crosstalk. J Clin Invest 1997; 100: 2158-69.
10. Ogihara T, Asano T, Ando K, et al. Angiotensin II induced insulin resistance is associated with enhanced insulin signaling. Hypertension 2002; 40: 872-9.
11. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784-92.
12. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.
13. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-66.
14. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363: 2022-31.
15. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-50.
16. DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355: 1551-62.
17. The TRANSCEND Investigators. Effects of the angiotensinreceptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008, 372: 1174-83.
18. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-6.
19. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001; 98: 2005-10.
20. Iwashima Y, Katsuya T, Ishikawa K, et al. Hypoaciponectinemia is an independent risk factor for hypertension. Hypertension 2004; 43: 1318-23.
21. Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S, Iwasaka T. Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. Thromb Res 2006; 117: 385-92.
22. Furuhashi M, Ura N, Higashiura K, et al. Blockade of the reninangiotensin system increases adiponectin concentration in patients with essential hypertension. Hypertension 2003; 42: 76-81.
23. Mori Y, Itho Y, Tajima N. Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes. Adv Ther 2007; 24: 146-53.
24. Yamada S, Ano N, Toda K, et al. Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro. Hypertens Res 2008; 31: 601-6.
25. Schupp M, Clemenz M, Gineste R, et al. Molecular characterization of new selective proxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 2005; 54: 3442-52.
26. Marshall TG, Lee RE, Marshall FE. Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b. Theor Biol Med Model. 2006; 3: 1.
27. Negro R, Formoso G, Hassan H. The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients. J Endocrinol Invest 2006; 29: 957-61.
28. Derosa G, Fogari E, D'Angelo A, et al. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. J Clin Pharm Ther 2007; 32: 261-8.
29. Delles C, Raff U, Mimran A, Fauvel JP, Ruilope LM, Schmieder RE. Effects of telmisartan and ramipril on adiponectin and blood pressure in patients with type 2 diabetes. Am J Hypertens 2008; 21: 1330-6.
30. Benndorf RA, Rudolph T, Appel D, et al. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism 2006; 55: 1159-64.
31. Nagel JM, Tietz AB, Goeke B, Parhofer KG. The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin- resistant subjects. Metabolism 2006; 55: 1149-54.
32. Vitale C, Mercuro G, Castiglioni C, et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005; 4: 6.
33. Giudicelli JF, Freslon JL, Glasson S, Richer C. Captopril and hypertension development in the SHR. Clin Exp Hypertens 1980; 2A: 1083-96.
34. Harrap SB, Van der Merwe WM, Griffin SA, Macpherson F, Lever AF. Brief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long-term. Hypertension 1990; 16: 603-14.
35. Wu JN, Berecek KH. Prevention of genetic hypertension by early treatment of spontaneously hypertensive rats with the angiotensin converting enzyme inhibitor captopril. Hypertension 1993; 22; 139-46.
36. Traub O, Lloyd MC, Webb RC. Long-term effects of brief antihypertensive treatment on systolic blood pressure and vascular reactivity in young genetically hypertensive rats. Cardiovasc Drugs Ther 1995; 9: 421-9.
37. Nakaya H, Sasamura H, Hayashi M, Saruta T. Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis. J Am Soc Nephrol 2001; 12: 659-66.
38. Nakaya H, Sasamura H, Mifune M, et al. Prepubertal treatment with angiotensin receptor blocker causes partial attenuation of hypertension and renal damage in adult Dahl salt-sensitive rats. Nephron 2002; 91: 710-18.
39. Ishiguro K, Sasamura H, Sakamaki Y, Itoh H, Saruta T. Development activity of the rennin-angiotensin system during the "critical period" modulates later L-NAME-induced hypertension and renal injury. Hypertens Res 2007; 30: 63-75.
40. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354: 1685-97.
41. Ishiguro K, Hayashi K, Sasamura H, Sakamaki Y, Itoh H. "Pulse" treatment with high-dose angiotensin blocker reversed renal arteriolar hypertrophy and regresses hypertension. Hypertension 2009; 53: 83-9.
42. The STAR CAST Investigators. The short treatment with the angiotensin receptor blocker candesartan surveyed by telemedicine (STAR CAST) study: rationale and study design. Hypertens Res 2008; 31: 1843-9.
43. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-28.
44. Devers MC, Campblee S, Shaw J, Zimmet P, Simmons D. Should liver function tests be included in definitions of metabolic syndrome? Evidence from the association between liver function tests, components of metabolic syndrome and prevalent cardiovascular disease. Diabet Med 2008; 25: 523-9.
45. Tamura Y, Tanaka Y, Sato F, et al. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2005; 90: 3191-6.
46. Sakurai M, Takamura T, Miura K, Kaneko S, Nakagawa H. Abnormal liver function tests and metabolic syndrome- Is fatty liver related to risks for atherosclerosis beyond obesity. Intern Med 2009; 8: 1573-4.
47. Ran J, Hirano T, Adachi M. Chronic ANG II infusion increases plasma triglyceride level by stimulating hepatic triglyceride production in rats. Am J Physiol Endocrinol Metab 2004; 287: E955-61.
48. Ran J, Hirano T, Adachi M. Angiotensin II type 1 receptor blocker ameliorated overproduction and accumulation of triglyceride in the liver of Zucker fatty rats. Am J Physiol Endocrinol Metab 2004; 287: 227-32.
49. Fujita K, Yoneda M, Wada K, et al. Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. Dig Dis Sci 2007; 52: 3455-64.
50. Hirose A, Ono M, Saibara T, et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 2007; 45: 1375-81.
51. Kurita S, Takamura T, Ota T, et al. Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects. Eur J Pharmacol 2008; 588: 316-24.
52. ozawa J, Sasaki T, Ohwada K, et al. Down-regulation of hepatic stearoyl-CoA desaturase 1 expression by angiotensin II receptor blocker in the obese fa/fa Zucker rat: possible role in amelioration of insulin resistance and hepatic steatosis. J Gastroenterol 2009; 44: 583-91.
53. Yoshiji J, Noguchi R, Ikenaka Y, et al. Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat. BMC Res Notes 2009; 2:70.
54. Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004; 40: 1222-5.
55. Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension- associated non-alcoholic steatohepatitis. World J Gastroenterol 2009; 28: 942-54.
56. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297-307.